🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Recruitingn/aAges 18 Years - anyAllUniversity Health Network, Toronto
NCT04151342 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the differ

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients ≥ 18 years at cancer diagnosis * Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations * Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \[PCR\] based next generation sequencing \[NGS\], immunohistochemistry \[IHC\], fluorescence in situ hybridization \[FISH\], liquid biopsy) * Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment Exclusion Criteria: * Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent
💊

What it tests

  • Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.
  • Patient-reported outcomes (PROs)
📍

Where

27 sites
Tom Baker Cancer Centre - University of Calgary - Alberta Health Services
Calgary, Canada
Cross Cancer Institute, University of Alberta - Alberta Health Services
Edmonton, Canada
BC Cancer
Vancouver, Canada
CancerCare Manitoba/University of Manitoba
Winnipeg, Canada
Dr. Everett Chalmers Regional Hospital
Fredericton, Canada
Dr. H. Bliss Murphy Cancer Centre
St. John's, Canada
Queen Elizabeth II (QEII) Health Sciences Centre
Halifax, Canada
William Osler Health System - Brampton Civic Hospital
Brampton, Canada

…and 19 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy